menu search

Dream-hf phase 3 trial results for mesoblast cell therapy in heart failure published in journal of the american college of cardiology (jacc)

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the...

February 27, 2023, 11:29 pm


Search within

Pages Search Results: